SCHEMBL1993077

SCHEMBL1993077

O=C1NC(=O)C(c2c[nH]c3ccsc23)=C1c1cn(C2CCN(CCF)CC2)c2ccccc12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CAMK2D Q13557 14/20 0.61
PRKCG P05129 11/20 0.61
PRKCB P05771 11/20 0.61
PRKCA P17252 11/20 0.61
PRKCE Q02156 11/20 0.61
PRKCH P24723 10/20 0.61
PRKCD Q05655 10/20 0.61
CAMK2B Q13554 8/20 0.61
CAMK2G Q13555 8/20 0.61
CAMK2A Q9UQM7 8/20 0.61
PRKCZ Q05513 7/20 0.61
SRC P12931 3/20 0.61
PRKACA P17612 7/20 0.51
PRKACB P22694 7/20 0.51
CDK2 P24941 2/20 0.51
PIP5K1C O60331 1/20 0.51
RPS6KA5 O75582 1/20 0.51
RPS6KA4 O75676 1/20 0.51
STK16 O75716 1/20 0.51
PAK3 O75914 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1992023 0.90 CAMK2D (0.59) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1989734 0.90 PRKCB (0.59) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1990615 0.90 CAMK2D (0.56) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1996178 0.90 CAMK2D (0.56) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1990883 0.87 CAMK2D (0.59) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1992525 0.87 CAMK2D (0.57) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1997192 0.86 PRKACA (0.56) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1991219 0.85 CAMK2D (0.56) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1990865 0.84 CAMK2D (0.45) CAMK2DPRKCGPRKCBPRKCAPRKCE
SCHEMBL1991852 0.82 PRKCB (0.59) CAMK2DPRKCGPRKCBPRKCAPRKCE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011079105-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-30 WO disclosed
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS ABBOTT LABORATORIES (US) 2011-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110152243-A1 NOVEL THIENOPYRROLE COMPOUNDS TPMT, TSLP, THPO CAMK2D 2963/4885PRKCG 3728/4885PRKCB 3335/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.